The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman’s disease-Reference-Cited by-同舟云学术

The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman’s disease

Published:2010-07-31 Issue:5 Volume:25 Page:444-447
ISSN:0910-8327
Container-title:Heart and Vessels
language:en
Short-container-title:Heart Vessels

Author:

Arita Yoh,Sakata Yasushi,Sudo Takao,Maeda Tetsuo,Matsuoka Ken,Tamai Keito,Higuchi Kaori,Shioyama Wataru,Nakaoka Yoshikazu,Kanakura Yuzuru,Yamauchi-Takihara Keiko

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00380-009-1215-5.pdf

Reference19 articles.

1. Herrada J, Cabanillas F, Rice L, Manning J, Pugh W (1998) The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 128:657–662

2. Peterson BA, Frizzera G (1993) Multicentric Castleman’s disease. Semin Oncol 20:636–647

3. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, Nakahata T, Kawai H, Tagoh H, Komori T, Kishimoto S, Hirano T, Kishimoto T (1989) Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood 74:1360–1367

4. Oka H, Ikeda S, Koga S, Miyahara Y, Kohno S (2008) Atorvastatin induces associated reductions in platelet P-selectin, oxidized low-density lipoprotein, and interleukin-6 in patients with coronary artery diseases Heart Vessels 23:249–256

5. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K, Hara M, Taguchi H, Kimura Y, Kato Y, Asaoku M, Kumagai S, Kodama F, Nakahara H, Hagihara K, Yoshizaki K, Kishimoto T (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106:2627–2632

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Drugs and Therapies in Pulmonary Arterial Hypertension;International Journal of Molecular Sciences;2023-03-19

2. Mendelian randomization study on causal association of IL-6 signaling with pulmonary arterial hypertension;Clinical and Experimental Hypertension;2023-03-05

3. Kynurenine metabolites predict survival in pulmonary arterial hypertension: A role for IL-6/IL-6Rα;Scientific Reports;2022-07-19

4. Text Mining-Based Drug Discovery for Connective Tissue Disease–Associated Pulmonary Arterial Hypertension;Frontiers in Pharmacology;2022-03-18

5. Mendelian randomisation and experimental medicine approaches to IL-6 as a drug target in PAH;European Respiratory Journal;2021-09-29